<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35894595</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Neutralizing Antibody Given after Paralysis Onset Reduces the Severity of Paralysis Compared to Nonspecific Antibody-Treated Controls in a Mouse Model of EV-D68-Associated Acute Flaccid Myelitis.</ArticleTitle><Pagination><StartPage>e0022722</StartPage><MedlinePgn>e0022722</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00227-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.00227-22</ELocationID><Abstract><AbstractText>Enterovirus D68 (EV-D68) can cause mild to severe respiratory illness and is associated with a poliomyelitis-like paralytic syndrome called acute flaccid myelitis (AFM). Most cases of EV-D68-associated AFM occur in young children who are brought to the clinic after the onset of neurologic symptoms. There are currently no known antiviral therapies for AFM, and it is unknown whether antiviral treatments will be effective if initiated after the onset of neurologic symptoms (when patients are likely to present for medical care). We developed a "clinical treatment model" for AFM, in which individual EV-D68-infected mice are tracked and treated with an EV-D68-specific human-mouse chimeric monoclonal antibody after the onset of moderate paralysis. Mice treated with antibody had significantly better paralysis outcomes compared to nonspecific antibody-treated controls. Treatment did not reverse paralysis that was present at the time of treatment initiation but did slow the further loss of function, including progression of weakness to other limbs, as well as reducing viral titer in the muscle and spinal cords of treated animals. We observed the greatest therapeutic effect in EV-D68 isolates which were neutralized by low concentrations of antibody, and diminishing therapeutic effect in EV-D68 isolates which required higher doses of antibody for neutralization. This work supports the use of virus-specific immunotherapy for the treatment of AFM. It also suggests that patients who present with AFM should be treated as soon as possible if recent infection with EV-D68 is suspected.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rudy</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-3936-6849</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6517-4966</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Penny</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyler</LastName><ForeName>Kenneth L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0003-3294-5888</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Microbiology, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Medical Center, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS101208</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000629404">acute flaccid myelitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020805" MajorTopicYN="N">Central Nervous System Viral Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009187" MajorTopicYN="N">Myelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009468" MajorTopicYN="N">Neuromuscular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EV-D68</Keyword><Keyword MajorTopicYN="N">acute flaccid myelitis</Keyword><Keyword MajorTopicYN="N">chimeric monoclonal antibody</Keyword><Keyword MajorTopicYN="N">delayed treatment</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">enterovirus D68</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35894595</ArticleId><ArticleId IdType="pmc">PMC9380545</ArticleId><ArticleId IdType="doi">10.1128/aac.00227-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lerner AM, DeRocco AJ, Yang L, Robinson DA, Eisinger RW, Bushar ND, Nath A, Erbelding E. 2021. Unraveling the mysteries of acute flaccid myelitis: scientific opportunities and priorities for future research. Clin Infect Dis 72:2044–2048. 10.1093/cid/ciaa1432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1432</ArticleId><ArticleId IdType="pmc">PMC8315125</ArticleId><ArticleId IdType="pubmed">32964217</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, Schreiner TL, Van Haren K, Yang M, Glaser CA, Tyler KL, Dominguez SR. 2016. Acute flaccid myelitis: a clinical review of US cases 2012–2015. Ann Neurol 80:326–338. 10.1002/ana.24730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24730</ArticleId><ArticleId IdType="pmc">PMC5098271</ArticleId><ArticleId IdType="pubmed">27422805</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Hu X-Y, Yu X-F. 2019. Current understanding of human enterovirus D68. Viruses 11:490. 10.3390/v11060490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11060490</ArticleId><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixon AM, Clarke P, Tyler KL. 2017. Evaluating treatment efficacy in a mouse model of enterovirus D68-associated paralytic myelitis. J Infect Dis 216:1245–1253. 10.1093/infdis/jix468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix468</ArticleId><ArticleId IdType="pmc">PMC5853295</ArticleId><ArticleId IdType="pubmed">28968718</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MR, Fu J, Kose N, Williamson LE, Bombardi R, Setliff I, Georgiev IS, Klose T, Rossmann MG, Bochkov YA, Gern JE, Kuhn RJ, Crowe JE, Jr.. 2020. Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease. Sci Immunol 5:eaba4902. 10.1126/sciimmunol.aba4902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aba4902</ArticleId><ArticleId IdType="pmc">PMC7418079</ArticleId><ArticleId IdType="pubmed">32620559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q, Zhu R, Xu L, He M, Yan X, Liu D, Yin Z, Wu Y, Li Y, Yang L, Hou W, Li S, Li Z, Chen Z, Li Z, Yu H, Gu Y, Zhang J, Baker TS, Zhou ZH, Graham BS, Cheng T, Li S, Xia N. 2019. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nat Microbiol 4:124–133. 10.1038/s41564-018-0275-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0275-7</ArticleId><ArticleId IdType="pmc">PMC6727974</ArticleId><ArticleId IdType="pubmed">30397341</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfferich J, Knoester M, Van Leer-Buter CC, Neuteboom RF, Meiners LC, Niesters HG, Brouwer OF. 2019. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr 178:1305–1315. 10.1007/s00431-019-03435-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-019-03435-3</ArticleId><ArticleId IdType="pmc">PMC6694036</ArticleId><ArticleId IdType="pubmed">31338675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>